Tests probiotic LR607 alongside chemoimmunotherapy before lung cancer surgery
Tests a probiotic with chemoimmunotherapy in adults with resectable non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed non-small cell lung cancer (stage IIA-IIIB) that can be removed by surgery. They would take the probiotic LR607 with chemoimmunotherapy before surgery.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Non-small cell lung cancer, stage IIA-IIIB, newly diagnosed, confirmed by tissue or cell tests. The tumor must be removable by surgery and have measurable lesions (RECIST v1.1).
- Earlier treatment
- People who have had immunotherapy before cannot join. Recent use of immunosuppressants is also not allowed.
Main reasons for not taking part
- Active autoimmune disease
- Recent use of immunosuppressants
- Interstitial lung disease
- Other cancers
- Active infection, pregnancy or drug allergies
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07534033, who can take part
Where in China
- Zhu Jiang Hospital of Southern Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zhujiang Hospital
- Trial code
- NCT07534033
- Record updated
- 29 October 2026
- Original description
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include:Read full original descriptionShow less
Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIA-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include:
Can LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment?
Participants will:
Take LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions
Inclusion: Histologically confirmed newly diagnosed patients; ECOG performance status 0-1; Age ≥18 years; Measurable lesions (RECIST v1.1); Organ function meeting the requirements for chemotherapy and immunotherapy.
Exclusion: Including active autoimmune diseases; Interstitial lung disease; Presence of other malignancies; History of immunotherapy; Active infection; Pregnancy or drug allergies; Recent use of immunosuppressants.